N-[(1S,9aR)(octahydro-2H-quinolizin-1-yl)methyl]-2,6-dimethylaniline | 1226915-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: N-[(1S,9aR)(octahydro-2H-quinolizin-1-yl)methyl]-2,6-dimethylaniline
• 英文别名: N-[[(1S,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl]-2,6-dimethylaniline
• CAS: 1226915-15-6
• 化学式: C₁₈H₂₈N₂
• 分子量: 272.434
• InChiKey: FIMLOFSRPSXWDG-DLBZAZTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,6-二甲基苯胺 、 bromolupinane 反应 36.0h， 以56%的产率得到N-[(1S,9aR)(octahydro-2H-quinolizin-1-yl)methyl]-2,6-dimethylaniline
  参考文献：
  名称：

  Novel Quinolizidinyl Derivatives as Antiarrhythmic Agents: 2. Further Investigation

  摘要：

  Fifteen quinolizidine derivatives have been tested for antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig (gp) heart tissues and to assess calcium antagonist activity. All compounds exhibited from moderate to high antiarrhythmic activity, and five of them (3, 4, 6, 13, and 15) were more active and potent than the reference drugs (amiodarone, lidocaine, procainamide, and quinidine). These compounds were studied on spontaneously beating Langendorff-perfuse gp heart; even at concentration 17-67 times higher than the Corresponding EC50 for antiarrhythmic activity, they prolonged the QT intervals only moderately, comparing favorably with amiodarone and quinidine. Compounds 3 and 15 deserve further investigation due to their interesting cardiovascular profiles.

  DOI：

  10.1021/jm100298d

文献信息

• Novel Quinolizidinyl Derivatives as Antiarrhythmic Agents: 2. Further Investigation
  作者：Bruno Tasso、Roberta Budriesi、Iana Vazzana、Pierfranco Ioan、Matteo Micucci、Federica Novelli、Michele Tonelli、Anna Sparatore、Alberto Chiarini、Fabio Sparatore

  DOI：10.1021/jm100298d

  日期：2010.6.24

  Fifteen quinolizidine derivatives have been tested for antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig (gp) heart tissues and to assess calcium antagonist activity. All compounds exhibited from moderate to high antiarrhythmic activity, and five of them (3, 4, 6, 13, and 15) were more active and potent than the reference drugs (amiodarone, lidocaine, procainamide, and quinidine). These compounds were studied on spontaneously beating Langendorff-perfuse gp heart; even at concentration 17-67 times higher than the Corresponding EC50 for antiarrhythmic activity, they prolonged the QT intervals only moderately, comparing favorably with amiodarone and quinidine. Compounds 3 and 15 deserve further investigation due to their interesting cardiovascular profiles.